Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?
Authors:
Open Access
- 15 May 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 23 (8) , 1830-1834
Abstract
An RCT among newly diagnosed, therapy naive women with polycystic ovary syndrome (PCOS) showed no significant differences in ovulation rate, ongoing pregnancy rate or spontaneous abortion rate in favour of clomifene citrate plus metformin compared with clomifene citrate. We wanted to assess whether there are specific subgroups of women with PCOS in whom clomifene citrate plus metformin leads to higher pregnancy rates. Subgroup analysis based on clinical and biochemical parameters of 111 women randomized to clomifene citrate plus metformin compared with 114 women randomized to clomifene citrate plus placebo. The data for age, BMI, waist–hip ratio (WHR) and plasma testosterone were available in all women, 2 h glucose in 80% of women and homeostatic model assessment for assessing insulin sensitivity (HOMA) in 50% of women. Of the women who were allocated to the metformin group, 44 women (40%) reached an ongoing pregnancy. In the placebo group, 52 women (46%) reached an ongoing pregnancy. There was a significantly different chance of an ongoing pregnancy for metformin versus placebo between subgroups based on age and WHR (P = 0.014). There was a positive effect of metformin versus placebo on pregnancy rate in older women (≥28 years) with a high WHR, a negative effect of metformin versus placebo in young women (<28 years) regardless of their WHR and no effect in older, not viscerally obese women. No significant differences in effect of treatment were found for groups based on BMI, 2 h glucose, HOMA or plasma testosterone. Metformin may be an effective addition to clomifene citrate in infertile women with PCOS, especially in older and viscerally obese patients.Keywords
This publication has 45 references indexed in Scilit:
- The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndromeBJOG: An International Journal of Obstetrics & Gynaecology, 2006
- Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trialBMJ, 2006
- Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes FederationDiabetic Medicine, 2006
- Predictors of abnormal glucose metabolism in women with polycystic ovary syndromeEuropean Journal of Endocrinology, 2006
- Use of insulin sensitizing agents in the treatment of polycystic ovary syndromeFertility and Sterility, 2004
- Ovarian Function and Metabolic Factors in Women with Oligomenorrhea Treated with Metformin in a Randomized Double Blind Placebo-Controlled TrialThe Journal of Clinical Endocrinology & Metabolism, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Insulin Reduction with Metformin Increases Luteal Phase Serum Glycodelin and Insulin-Like Growth Factor-Binding Protein 1 Concentrations and Enhances Uterine Vascularity and Blood Flow in the Polycystic Ovary SyndromeThe Journal of Clinical Endocrinology & Metabolism, 2001
- A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasian Women from SpainThe Journal of Clinical Endocrinology & Metabolism, 2000
- Decreases in Ovarian Cytochrome P450c17α Activity and Serum Free Testosterone after Reduction of Insulin Secretion in Polycystic Ovary SyndromeNew England Journal of Medicine, 1996